284 related articles for article (PubMed ID: 8687151)
41. Parenteral nutrition support for patients with pancreatic cancer--improvement of the nutritional status and the therapeutic outcome.
Richter E; Denecke A; Klapdor S; Klapdor R
Anticancer Res; 2012 May; 32(5):2111-8. PubMed ID: 22593497
[TBL] [Abstract][Full Text] [Related]
42. Lack of an antitumoral effect of immunomodulatory galactoside-specific mistletoe lectin on N-methyl-N-nitrosourea-induced urinary bladder carcinogenesis in rats.
Kunze E; Schulz H; Ahrens H; Gabius HJ
Exp Toxicol Pathol; 1997 Aug; 49(3-4):167-80. PubMed ID: 9314050
[TBL] [Abstract][Full Text] [Related]
43. [Iscucin--mistletoe preparations for the pre- and postoperative treatment of malignancies. Documentation No. 21].
Kast A; Hauser SP
Schweiz Rundsch Med Prax; 1990 Apr; 79(14):427-9. PubMed ID: 2343229
[TBL] [Abstract][Full Text] [Related]
44. [Vysorel/Isorel--cancer drug from Viscum album. Documentation No.20].
Kast A; Hauser SP
Schweiz Rundsch Med Prax; 1990 Mar; 79(11):332-4. PubMed ID: 2315589
[TBL] [Abstract][Full Text] [Related]
45. Hormonal treatment of unresectable pancreatic cancer with LHRH analogue (goserelin).
Sperti C; Pasquali C; Catalini S; Cappellazzo F; Bonadimani B; Militello C; Pedrazzoli S
Eur J Surg Oncol; 1992 Jun; 18(3):267-71. PubMed ID: 1535051
[TBL] [Abstract][Full Text] [Related]
46. Recognition of different antigens of mistletoe extracts by anti-mistletoe lectin antibodies.
Stein GM; Pfüller U; Berg PA
Cancer Lett; 1999 Jan; 135(2):165-70. PubMed ID: 10096425
[TBL] [Abstract][Full Text] [Related]
47. [Immunoactive effects of various mistletoe lectin-1 dosages in mammary carcinoma patients].
Beuth J; Stoffel B; Ko HL; Buss G; Tunggal L; Pulverer G
Arzneimittelforschung; 1995 Apr; 45(4):505-7. PubMed ID: 7779151
[TBL] [Abstract][Full Text] [Related]
48. Effects of a lectin- and a viscotoxin-rich mistletoe preparation on clinical and hematologic parameters: a placebo-controlled evaluation in healthy subjects.
Huber R; Klein R; Berg PA; Lüdtke R; Werner M
J Altern Complement Med; 2002 Dec; 8(6):857-66. PubMed ID: 12614536
[TBL] [Abstract][Full Text] [Related]
49. Mistletoe extracts standardised in terms of mistletoe lectins (ML I) in oncology: current state of clinical research.
Stauder H; Kreuser ED
Onkologie; 2002 Aug; 25(4):374-80. PubMed ID: 12232491
[TBL] [Abstract][Full Text] [Related]
50. Quality of life of patients with advanced pancreatic cancer during treatment with mistletoe: a randomized controlled trial.
Tröger W; Galun D; Reif M; Schumann A; Stanković N; Milićević M
Dtsch Arztebl Int; 2014 Jul; 111(29-30):493-502, 33 p following 502. PubMed ID: 25142075
[TBL] [Abstract][Full Text] [Related]
51. Clinical relevance of immunoactive mistletoe lectin-I.
Beuth J
Anticancer Drugs; 1997 Apr; 8 Suppl 1():S53-5. PubMed ID: 9179369
[TBL] [Abstract][Full Text] [Related]
52. [Effect of mistletoe lectin therapy on serum level of defined serum proteins (acute phase proteins) in tumor patients].
Beuth J; Gabius HJ; Steuer MK; Geisel J; Steuer M; Ko HL; Pulverer G
Med Klin (Munich); 1993 May; 88(5):287-90. PubMed ID: 7687001
[TBL] [Abstract][Full Text] [Related]
53. Mistletoe extract standardized for the galactoside-specific lectin (ML-1) induces beta-endorphin release and immunopotentiation in breast cancer patients.
Heiny BM; Beuth J
Anticancer Res; 1994; 14(3B):1339-42. PubMed ID: 8067703
[TBL] [Abstract][Full Text] [Related]
54. Targeting inflammation in cancer-related-fatigue: a rationale for mistletoe therapy as supportive care in colorectal cancer patients.
Bock PR; Hanisch J; Matthes H; Zänker KS
Inflamm Allergy Drug Targets; 2014; 13(2):105-11. PubMed ID: 24766319
[TBL] [Abstract][Full Text] [Related]
55. [Mistletoe therapy from the pharmacologic perspective].
Hajto T; Hostanska K; Saller R
Forsch Komplementarmed; 1999 Aug; 6(4):186-94. PubMed ID: 10529578
[TBL] [Abstract][Full Text] [Related]
56. Mistletoe lectins: telomerase inhibitors in alternative cancer therapy.
Li SS
Drug Discov Today; 2002 Sep; 7(17):896-7. PubMed ID: 12546929
[No Abstract] [Full Text] [Related]
57. Quality of life in breast cancer patients during chemotherapy and concurrent therapy with a mistletoe extract.
Eisenbraun J; Scheer R; Kröz M; Schad F; Huber R
Phytomedicine; 2011 Jan; 18(2-3):151-7. PubMed ID: 20724129
[TBL] [Abstract][Full Text] [Related]
58. Retrolective studies on the survival of cancer patients treated with mistletoe extracts: a meta-analysis.
Ostermann T; Büssing A
Explore (NY); 2012; 8(5):277-81. PubMed ID: 22938746
[TBL] [Abstract][Full Text] [Related]
59. Development and validation of an instrument to measure the effects of a mistletoe preparation on quality of life of cancer patients: the Life Quality Lectin-53 (LQL-53) Questionnaire.
Kirchberger I; Wetzel D; Finger T
Qual Life Res; 2004 Mar; 13(2):463-79. PubMed ID: 15085919
[TBL] [Abstract][Full Text] [Related]
60. Induction of anti-mistletoe lectin antibodies in relation to different mistletoe-extracts.
Stein GM; Stettin A; Schultze J; Berg PA
Anticancer Drugs; 1997 Apr; 8 Suppl 1():S57-9. PubMed ID: 9179370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
